Asian Diversity Clinical Trials: FOMAT Partners With Dr. Than Luu
Asian diversity clinical trials are at the center of a groundbreaking new partnership between FOMAT and Dr. Than Luu, a distinguished family medicine practitioner in the Greater Los Angeles Area. This collaboration represents a significant step forward in FOMAT’s mission to promote diversity and inclusivity in clinical research, targeting a demographic that has historically been underrepresented in studies that shape modern medicine.
A Strategic Partnership Focused on Asian Diversity Clinical Trials
Dr. Luu’s new site, located in the Greater Los Angeles Area — a region celebrated for its rich cultural and ethnic diversity — will become a vital part of FOMAT’s extensive research network. With almost two decades of clinical experience, Dr. Luu is well regarded for his compassionate, patient centered approach and his commitment to serving diverse communities.
Fluent in English, Cantonese, Vietnamese, and Spanish, Dr. Luu’s practice has long served patients from various ethnic backgrounds. This multilingual proficiency ensures that language barriers do not prevent access to essential healthcare services — a critical advantage when expanding Asian diversity clinical trials to communities that have traditionally been difficult to reach.
Simon Corman, Chief Growth Officer at FOMAT, highlighted the significance of the partnership: “This partnership is a testament to our unwavering commitment to empower diversity and inclusivity in clinical trials. His expertise and the new site’s strategic location allow us to deepen our engagement with another vibrant ethnic community. It is an honor to work alongside Dr. Luu, broadening our horizons and furthering our mission to innovate healthcare.”
Dr. Luu echoed that enthusiasm: “Partnering with FOMAT allows me to leverage my background for the betterment of clinical research, especially for the Asian community. Being part of this extensive network and contributing to more inclusive healthcare advancements is genuinely rewarding.”
Why Asian Diversity Clinical Trials Matter
For FOMAT, inclusivity is not just a goal — it is a core part of their mission. Diverse participation in clinical trials is essential to developing treatments that are safe and effective for people of all backgrounds. Historically, many ethnic groups including the Asian community have been underrepresented in clinical research, creating gaps in understanding how treatments affect different populations.
This partnership directly addresses those gaps by providing more opportunities for Asian patients to participate in research. By locating the site in the Greater Los Angeles Area and leveraging Dr. Luu’s deep community relationships, FOMAT ensures that underrepresented populations gain access to cutting edge therapies from the earliest phases of development.
Sponsors and CROs benefit as well — access to a patient population that reflects the diversity increasingly required by updated FDA guidance is a competitive advantage that only a select number of sites can offer.
A Centralized and Fully Integrated Model
FOMAT operates under a centralized and fully integrated model, ensuring that every site within the network maintains consistent quality, efficiency, and data integrity. Dr. Luu’s site will benefit from this infrastructure, providing the same high standard of clinical research that FOMAT is known for across its national network.
Dr. Luu’s site joins a network that stretches across multiple states, giving sponsors and CROs valuable access to diverse patient populations at scale. For patients in Dr. Luu’s community, this collaboration offers a unique opportunity to receive cutting edge treatments close to home — aligning directly with Dr. Luu’s commitment to patient first care.
Benefits for Sponsors, CROs, and Patients
For industry sponsors and CROs, this partnership provides direct access to a segment of the population that has traditionally been challenging to enroll in Asian diversity clinical trials. Diversifying clinical trial participants leads to a more comprehensive understanding of how treatments perform across different demographics, ultimately contributing to safer and more effective therapies.
For patients, the benefits are equally meaningful. Individuals within the Asian community now have increased access to clinical trials, early access to innovative treatments, and the opportunity to contribute to research that directly benefits their community.
To learn more about how FOMAT is expanding access to clinical research across the United States, visit our Physician Investigator Network page or explore our Active Studies to find current opportunities near you.
Read the full press release: Bridging Asian Diversity in Clinical Trials: FOMAT and Dr. Than Luu.